Stock NGNE NEUROGENE INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Neurogene Inc.

Equities

NGNE

US64135M1053

Delayed Nasdaq
Other stock markets
 21:00:00 29/04/2024 BST 		5-day change 1st Jan Change
33.4 USD +11.48% Intraday chart for Neurogene Inc. +9.11% +72.34%
04-29 Leerink Partners Starts Neurogene With Outperform Rating, $46 Price Target MT
03-22 North American Morning Briefing : Stocks Struggle After New Records DJ

Evolution of the average Target Price on Neurogene Inc.

Price target over the last 5 years

History of analyst recommendation changes

2dd2c78cb366c1b96c589753784ed9.PUy55DLl1WDpHmf7Ut6d9DTFRom7PHrPrewAEi1v_5o.Wx6ArXqdtAibWgi-HYbKl2b9ftPBDyqKx9l0W2oNluh2ANS1eqGbDqh2Vw~e3248ae36ca43679034f22594eb9c3a1

Analyst Recommendations on Neurogene Inc.

Leerink Partners Starts Neurogene With Outperform Rating, $46 Price Target MT
William Blair Initiates Neurogene With Outperform Rating MT
HC Wainwright Starts Neurogene With Buy Rating, $45 Price Target MT
Stifel Starts Coverage on Neurogene with Buy Rating, $31 Price Target MT
Mizuho Adjusts Price Target on Neoleukin Therapeutics to $1.50 From $2, Keeps Neutral Rating MT
North American Morning Briefing : Stock Futures Dip as Higher Rate Fears Persist DJ
Guggenheim Downgrades Neoleukin Therapeutics to Neutral From Buy MT
Mizuho Downgrades Neoleukin Therapeutics to Neutral From Buy, Adjusts Price Target to $2 From $21 MT
Canaccord Genuity Downgrades Neoleukin Therapeutics to Hold From Buy, Adjusts Price Target to $1 From $10 MT
BofA Securities Downgrades Neoleukin Therapeutics to Underperform From Buy, Adjusts Price Target to $1 From $3 MT
HC Wainwright Adjusts Neoleukin Therapeutics' Price Target to $6 from $22, Maintains Buy Rating MT
Stifel Nicolaus Adjusts Price Target for Neoleukin Therapeutics to $14 From $18, Maintains Buy Rating MT
Canaccord Genuity Assumes Neoleukin Therapeutics at Buy with $10 Price Target MT
Piper Sandler Adjusts Price Target on Neoleukin Therapeutics to $6 From $25, Reiterates Overweight Rating MT
Guggenheim Adjusts Price Target for Neoleukin Therapeutics to $12 From $16, Maintains Buy Rating MT
Piper Sandler Adjusts Neoleukin Therapeutics Price Target to $25 From $30, Maintains Overweight Rating MT
NEOLEUKIN THERAPEUTICS : Piper Sandler Starts Neoleukin Therapeutics at Overweight with $30 Price Target MT
NEOLEUKIN THERAPEUTICS : Stifel Starts Neoleukin Therapeutics at Buy With $18 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
33.4 USD
Average target price
53.33 USD
Spread / Average Target
+59.68%
High Price Target
61 USD
Spread / Highest target
+82.63%
Low Price Target
44 USD
Spread / Lowest Target
+31.74%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Neurogene Inc.

Leerink Partners
William Blair & Co.
HC Wainwright
Stifel Nicolaus
Mizuho Securities
Guggenheim
Canaccord Genuity
BofA Securities
Piper Sandler

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. NGNE Stock
  4. Consensus Neurogene Inc.